4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Altimmune, Inc. (ALT) operates in the Biotechnology industry and is headquartered in Gaithersburg, United States with about 57 employees. Its market capitalization is roughly $552 million. In the fiscal year ended 2025-12-31, ALT reported $0M in revenue and ($88M) in net income.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Interactive charts & full statements → Open the ALT valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | ($0M) | — |
| Operating Income (EBIT) | ($94M) | ($103M) | ($84M) | ($88M) | — |
| Net Income | ($88M) | ($95M) | ($88M) | ($85M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($24M) | ($29M) | ($21M) | ($23M) | ($22M) |
| Net Income | ($23M) | ($27M) | ($19M) | ($22M) | ($20M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $280M | $139M | $211M | $207M | — |
| Total Liabilities | $55M | $16M | $16M | $22M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALT viewer.
About TickerBase · Data methodology & sources